Surveying the Landscape for Active Surveillance
This article was originally published in RPM Report
The transition away from spontaneous adverse event reporting systems to real-time active surveillance is under way, but far from complete. Alan Goldhammer, the former head of regulatory affairs at the Pharmaceutical Research & Manufacturers of America trade association, surveys the landscape of active surveillance activities.
You may also be interested in...
The past decade has witnessed the importance of DTC pharma messages. With social media tracking and internet search signal detection, is the US at the edge of a DFC era? Will safety signals scraped from internet inquiries and social media conversations be the next wave source of drug safety concerns? A special subcommittee of FDA’s Science Board released a report at the beginning of May that advises FDA to pay attention to the opportunities from new media for picking up drug safety signals.
Bristol-Myers Squibb/AstraZeneca Onglyza is Guinea Pig for FDA Mini-Sentinel Post-Market Surveillance
FDA’s Congressionally-mandated active surveillance system, Sentinel, is ready for shakedown cruises in 2011. One of the first projects will be a close examination of real-world experience and cardiovascular events associated with saxagliptin. That’s a dubious distinction for BMS/AZ, the co-marketers of Onglyza–but it also sets up a new dynamic that all sponsors should watch.
The Reagan-Udall Foundation is the one piece of the FDA drug safety law enacted in 2007 that both FDA and industry are excited about. Congressional appropriators, however, have serious concerns. The stakes are higher than they seem: in the short run, the Critical Path and active surveillance systems may depend on the foundation. In the long run, the question is whether industry has any say in the evolution of regulation.